Microbio was founded in year 2000. Since then, Microbio has dedicated to new drug development and adapting new concepts for fulfillment of better human health, also to creating greater values for customers and company shareholders.

Microbio provides wide varieties of health products in fields such as enhancing immunity, and maintaining vitality and health to the general public. In new botanical drug discovery, our goal is to produce high-valued prescription drugs with high efficacy and less side effects. In health supplements, we focused on disease prevention and nutrients supplement. In production, we do supply raw materials to many of Taiwan's pharmaceutical companies.

With our platform technology in bio-transformation, we take the advantage of symbiotic fermentation process and apply to many of our products. Currently there are several products in clinical trials: MS-20 (fermented soybean extract) is in phase III and Phase II trials for enhancing NK (natural killer) cells in cancer patients and for improving the quality of lives of liver cancer patients, respectively. Herbiron (four ingredient ion supplement) is in phase III trials for treating iron deficiency anemia.WH-1 (botanical drug) is in phase II trials for diabetic wound healing.

Being a leader in modern botanical and biotransformation drug companies, Microbio is setting up its future goals as "Marketing products around the world to create values; Becoming a sustainable enterprise and Establishing the Taiwan biotech/pharma industry as a force to be reckoned with internationally".